Triterpenoids from Momordica balsamina with a Collateral Sensitivity Effect for Tackling Multidrug Resistance in Cancer Cells

Abstract

The collateral sensitivity effect is among the most promising strategies for overcoming multidrug resistance in cancer. In this work, 28 cucurbitane-type triterpenoids (1–28), previously isolated from the African medicinal plant Momordica balsamina and its derivatives, were evaluated for their collateral sensitivity effect on three different human cancer entities, gastric (EPG85-257), pancreatic (EPP85-181), and colon (HT-29), each with two different multidrug-resistant variants. One was selected for its resistance to daunorubicin (EPG85-257RDB, EPP85-181RDB, HT-29RDB) and the other was selected for its resistance to mitoxantrone (EPG85-257RNOV, EPP85-181RNOV, HT-29RNOV). On gastric cell lines, the best results were obtained for compounds 3 and 10, which exhibited a collateral sensitivity effect together with high antiproliferative activity. In turn, on colon cancer cell lines, the best multidrug resistance-selective antiproliferative effects were observed for derivatives 11, 13, and 15, which showed collateral sensitivity effects against both resistant variants. Compounds 11 and 3 were also the most selective against the multidrug resistance pancreatic cells lines. Some compounds, such 6, 10, 11 and 15, were previously found to be strong P-glycoprotein modulators, thus highlighting their potential as promising leads for overcoming multidrug resistance in cancer cells.

Key words

Momordica balsamina - Cucurbitaceae - collateral sensitivity - antiproliferative activity - multidrug resistance - triterpenes

• References

• 1 Szakács G, Hall MD, Gottesman MM, Boumendjel A, Kachadourian R, Day BJ, Baubichon-Cortay H, Di Pietro A. Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev 2014; 114: 5753-5774
• 2 Gottesman MM, Lavi O, Hall MD, Gillet JP. Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol 2016; 56: 85-102
• 3 Lagas JS, van Waterschoot RAB, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010; 9: 319-326
• 4 Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MAJ, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JHM. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 2008; 7: 2280-2287
• 5 Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updat 2005; 8: 15-26
• 6 Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 2013; 31: 1397-1407
• 7 Klukovits A, Krajcsi P. Mechanisms and therapeutic potential of inhibiting drug efflux transporters. Expert Opin Drug Metab Toxicol 2015; 11: 907-920
• 8 Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat 2012; 15: 98-105
• 9 Thakur GS, Bag M, Sanodiya BS, Bhadouriya P, Debnath M, Prasad GB, Bisen PS. Momordica balsamina: a medicinal and neutraceutical plant for health care management. Curr Pharm Biotechnol 2009; 10: 667-682
• 10 Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep 2005; 22: 386-399
• 11 Dandawate PR, Subramaniam D, Padhye SB, Anant S. Bitter melon: a panacea for inflammation and cancer. Chin J Nat Med 2016; 14: 81-100
• 12 Ramalhete C, Molnár J, Mulhovo S, Rosário VE, Ferreira MJU. New potent P-glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells. Bioorg Med Chem 2009; 17: 6942-6951
• 13 Ramalhete C, Mulhovo S, Molnar J, Ferreira MJU. Triterpenoids from Momordica balsamina: Reversal of ABCB1-mediated multidrug resistance. Bioorg Med Chem 2016; 24: 5061-5067
• 14 Ramalhete C, Spengler G, Martins A, Martins M, Viveiros M, Mulhovo S, Ferreira MJU, Amaral L. Inhibition of efflux pumps in methicillin-resistant Staphylococcus aureus and Enterococcus faecalis resistant strains by triterpenoids from Momordica balsamina . Int J Antimicrob Agents 2011; 37: 70-74
• 15 Reis MA, Ahmed OB, Spengler G, Molnár J, Lage H, Ferreira MJU. Exploring jolkinol D derivatives to overcome multidrug resistance in cancer. J Nat Prod 2017; 80: 1411-1420
• 16 Reis MA, Ahmed OB, Spengler G, Molnár J, Lage H, Ferreira MJU. Jatrophane diterpenes and cancer multidrug resistance – ABCB1 efflux modulation and selective cell death induction. Phytomedicine 2016; 23: 968-978
• 17 Reis MA, Paterna A, Ferreira RJ, Lage H, Ferreira MJU. Macrocyclic diterpenes resensitizing multidrug resistant phenotypes. Bioorg Med Chem 2014; 22: 3696-3702
• 18 Paterna A, Kincses A, Spengler G, Mulhovo S, Molnár J, Ferreira MJU. Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells. Eur J Med Chem 2017; 128: 247-257
• 19 Ferreira MJU, Duarte N, Reis M, Madureira AM, Molnár J. Euphorbia and Momordica metabolites for overcoming multidrug resistance. Phytochem Rev 2014; 13: 915-935
• 20 Matos AM, Reis M, Duarte N, Spengler G, Molnár J, Ferreira MJU. Epoxylathyrol derivatives: modulation of ABCB1-mediated multidrug resistance in human colon adenocarcinoma and mouse T-lymphoma cells. J Nat Prod 2015; 78: 2215-2228
• 21 Ramalhete C, da Cruz FP, Lopes D, Mulhovo S, Rosário VE, Prudêncio M, Ferreira MJU. Triterpenoids as inhibitors of erythrocytic and liver stages of Plasmodium infections. Bioorg Med Chem 2011; 19: 7474-7481
• 22 Ramalhete C, Lopes D, Mulhovo S, Molnár J, Rosário VE, Ferreira MJU. New antimalarials with a triterpenic scaffold from Momordica balsamina . Bioorg Med Chem 2010; 18: 5254-5260
• 23 Ramalhete C, Mansoor TA, Mulhovo S, Molnár J, Ferreira MJU. Cucurbitane-type triterpenoids from the African plant Momordica balsamina . J Nat Prod 2009; 72: 2009-2013
• 24 Ramalhete C, Lopes D, Molnár J, Mulhovo S, Rosário VE, Ferreira MJU. Karavilagenin C derivatives as antimalarials. Bioorg Med Chem 2011; 19: 330-338
• 25 Duarte N, Lage H, Abrantes M, Ferreira MJU. Phenolic compounds as selective antineoplasic agents against multidrug-resistant human cancer cells. Planta Med 2010; 76: 975-980
• 26 Lage H, Duarte N, Coburger C, Hilgeroth A, Ferreira MJU. Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells. Phytomedicine 2010; 17: 441-448
• 27 Hilgeroth A, Baumert C, Coburger C, Seifert M, Krawczyk S, Hempel C, Neubauer F, Krug M, Molnár J, Lage H. Novel structurally varied N-alkyl 1,4-dihydropyridines as ABCB1 inhibitors: structure-activity relationships, biological activity and first bioanalytical evaluation. Med Chem 2013; 9: 487-493
• 28 Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 2009; 30: 546-556
• 29 Lage H. Proteomic approaches for investigation of therapy resistance in cancer. Proteomics. Clin Appl 2009; 3: 883-911
• 30 Lage H, Aki-Sener E, Yalcin I. High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drug. Int J Cancer 2006; 119: 213-220